LncRNA TUG1/miR-377途径调控肾小管EMT对糖尿病肾病肾间质纤维化的影响及芪葵颗粒干预作用研究
批准号:
82004286
项目类别:
青年科学基金项目
资助金额:
24.0 万元
负责人:
严倩华
依托单位:
学科分类:
中医内科学
结题年份:
2023
批准年份:
2020
项目状态:
已结题
项目参与者:
严倩华
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
肾小管上皮间质转分化(EMT)是糖尿病肾病(DN)肾间质纤维化早期事件。芪葵颗粒能抑制肾小管EMT,但分子机制不明。RNA之间相互作用是调控肾小管EMT的重要机制。前期研究表明,TUG1是芪葵颗粒干预DN小鼠后肾组织高表达的LncRNA。TUG1与miR-377有结合位点,PPARγ是miR-377的靶基因。芪葵颗粒能上调TUG1和PPARγ,下调miR-377表达。我们推测,芪葵颗粒可能通过TUG1/miR-377途径调控肾小管EMT,发挥抗DN肾间质纤维化的作用。本课题拟进行:高糖诱导肾小管EMT,采用沉默、过表达、双荧光素酶报告基因等技术,验证TUG1竞争性结合miR-377,上调PPARγ,抑制肾小管EMT。进一步证实芪葵颗粒通过TUG1/miR-377途径抑制肾小管EMT。采用db/db小鼠DN模型,明确芪葵颗粒抑制肾间质纤维化的效应环节及作用靶点,为中医药防治DN提供科学依据。
英文摘要
Renal tubular epithelial mesenchymal transition (EMT) is an early event of renal interstitial fibrosis in diabetic nephropathy (DN). Qikui granules can inhibit renal tubular EMT, but the mechanism is unknown. The interaction between RNAs is an important mechanism for regulation of renal tubular EMT. Previous studies showed that TUG1 is a highly expressed lncRNA in kidney tissue of DN mice after intervention of Qikui granules; there are binding sites between TUG1 and miR-377; PPARγ is the target gene of miR-377; Qikui granules can up-regulate the expression of TUG1 and PPARγ and down-regulate the expression of miR-377. We speculate that Qikui granules may regulate renal tubular EMT through TUG1/miR-377 pathway, and inhibit renal interstitial fibrosis. In this subject, we induce renal tubular EMT by high glucose, use technologies of silence/overexpression, double luciferase reporter gene and et al to verify the competitive binding of TUG1 to miR-377, up-regulate PPARγ, inhibit renal tubular EMT. We confirm that Qikui granules inhibit renal tubular EMT through TUG1/miR-377/PPARγ. Using the db/db mouse DN model, we verify the effective link and target of Qikui granules in inhibiting renal interstitial fibrosis, which provides scientific basis for prevention and treatment of DN by traditional Chinese medicine.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:https://doi.org/10.1016/j.biopha.2023.116039.
发表时间:2024
期刊:Biomedicine & Pharmacotherapy
影响因子:--
作者:Li Song;Wei Zhang;Shi-yun Tang;Si-min Luo;Pei-yu Xiong;Jun-yu Liu;Heng-chang Hu;Ying-qi Chen;Bo Jia;Qian-hua Yan;Song-qi Tang;Wei Huang
通讯作者:Wei Huang
DOI:--
发表时间:2023
期刊:现代药物与临床
影响因子:--
作者:俞凡;王一清;戴国梁;严倩华;曹阳;余江毅
通讯作者:余江毅
DOI:10.3389/fphar.2023.1288159
发表时间:2023
期刊:FRONTIERS IN PHARMACOLOGY
影响因子:5.6
作者:Tan, Ying;Zhang, Ziqi;Zhou, Peipei;Zhang, Qiling;Li, Nan;Yan, Qianhua;Huang, Liji;Yu, Jiangyi
通讯作者:Yu, Jiangyi
DOI:--
发表时间:2023
期刊:中成药
影响因子:--
作者:谭莹;李楠;严倩华;周希乔;余江毅
通讯作者:余江毅
DOI:10.3389/fendo.2023.1166880
发表时间:2023
期刊:Frontiers in endocrinology
影响因子:5.2
作者:
通讯作者:
国内基金
海外基金















{{item.name}}会员


